Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
Jierui Liu (Liu J), Yanqing Liu (Liu Y), Yansong Lin (Lin Y), Jun Liang (Liang J)
Endocrinol Metab. 2019;34(3):215-225.   Published online 2019 Sep 26     DOI: https://doi.org/10.3803/EnM.2019.34.3.215
Citations to this article as recorded by Crossref logo
Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial
Yan-Song Lin, Hui Yang, Yong Ding, Yi-Zhuang Cheng, Feng Shi, Jian Tan, Zhi-Yong Deng, Zhen-Dong Chen, Rong-Fu Wang, Qing-Hai Ji, Rui Huang, Lin-Fa Li
Thyroid.2021; 31(4): 607.     CrossRef
Radioactive iodine therapy may not improve disease‐specific survival in follicular variant papillary thyroid cancer without distant metastasis: A propensity score‐matched analysis
Xiaofei Wang, Xun Zheng, Jingqiang Zhu, Zhihui Li, Tao Wei
Head & Neck.2021; 43(6): 1730.     CrossRef
Serum CYFRA 21.1 Level Predicts Disease Course in Thyroid Cancer with Distant Metastasis
Chaiho Jeong, Jeongmin Lee, Hyukjin Yoon, Jeonghoon Ha, Min-Hee Kim, Ja-Seong Bae, Chan-Kwon Jung, Jeong-Soo Kim, Moo-Il Kang, Dong-Jun Lim
Cancers.2021; 13(4): 811.     CrossRef
Radio-Iodide Treatment: From Molecular Aspects to the Clinical View
Antonio De la Vieja, Garcilaso Riesco-Eizaguirre
Cancers.2021; 13(5): 995.     CrossRef
TNFα-mediated activation of NF-κB downregulates sodium-iodide symporter expression in thyroid cells
Márcia Faria, Rita Domingues, Francisca Paixão, Maria João Bugalho, Paulo Matos, Ana Luísa Silva, Salvatore Papa
PLOS ONE.2020; 15(2): e0228794.     CrossRef
Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review
Mohammad Al-Jundi, Shilpa Thakur, Sriram Gubbi, Joanna Klubo-Gwiezdzinska
Cancers.2020; 12(8): 2104.     CrossRef
Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy
Maaike Dotinga, Dennis Vriens, Floris van Velden, Linda Heijmen, James Nagarajah, Rodney Hicks, Ellen Kapiteijn, Lioe-Fee de Geus-Oei
The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2020;[Epub]     CrossRef
Mediator complex subunit 16 is down-regulated in papillary thyroid cancer, leading to increased transforming growth factor-β signaling and radioiodine resistance
Hongwei Gao, Peirong Bai, Lin Xiao, Mengjia Shen, Qiuxiao Yu, Yuanyuan Lei, Wenting Huang, Xiang Lin, Xinyi Zheng, Tao Wei, Yong Jiang, Feng Ye, Hong Bu
Journal of Biological Chemistry.2020; 295(31): 10726.     CrossRef
Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer
Dong Yun Lee, Yong-il Kim
Clinical Nuclear Medicine.2020; 45(8): 604.     CrossRef
Combination of peroxisome proliferator–activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells
Jui-Yu Chen, Jane-Jen Wang, Hsin-Chen Lee, Chin-Wen Chi, Chen-Hsen Lee, Yi-Chiung Hsu
Journal of the Chinese Medical Association.2020; 83(10): 923.     CrossRef